信隆健康(002105) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 511,351,040.77, a decrease of 12.67% compared to CNY 585,539,472.88 in the same period last year[3] - Net profit attributable to shareholders was CNY 45,395,423.02, down 23.57% from CNY 59,397,700.22 year-on-year[3] - The basic earnings per share decreased by 23.31% to CNY 0.125 from CNY 0.163 in the same period last year[3] - The total comprehensive income for the period was CNY 52,007,488.29, compared to CNY 65,337,683.13 in the previous year, reflecting a decline of 20.5%[17] - The operating profit for Q1 2022 was CNY 57,840,592.69, down from CNY 70,429,974.32 in Q1 2021, representing a decline of 18.3%[17] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 15,248,893.03, compared to a negative cash flow of CNY -15,971,124.05 in the previous year, marking a 195.48% increase[3] - Cash and cash equivalents at the end of Q1 2022 were CNY 458,910,565.65, slightly down from CNY 459,199,753.69 at the beginning of the year[12] - Cash and cash equivalents at the end of the period amounted to CNY 458,910,565.65, a decrease from CNY 328,185,548.88 in the previous year[21] - The cash flow from operating activities showed a net inflow of CNY 15,248,893.03, recovering from a net outflow of CNY 15,971,124.05 in the same period last year[21] - The cash flow from investing activities showed a net outflow of CNY 14,125,948.38, improving from a net outflow of CNY 16,617,126.12 in the previous year[21] Assets and Liabilities - Total assets decreased by 5.67% to CNY 2,153,063,155.26 from CNY 2,282,516,393.71 at the end of the previous year[3] - Total liabilities decreased to CNY 1,157,427,705.21 from CNY 1,338,888,575.65, indicating a reduction of 13.5%[14] - Accounts receivable decreased to CNY 562,278,462.67 from CNY 636,496,632.73, a decline of 11.6%[13] - Inventory levels decreased to CNY 390,997,894.87 from CNY 435,013,849.64, reflecting a reduction of 10.1%[13] Shareholder Equity - The company's equity attributable to shareholders increased by 5.33% to CNY 898,415,685.89 from CNY 852,946,415.37 at the end of the previous year[3] - The weighted average return on equity fell to 5.18%, down 3.51% from 8.69% in the previous year[3] Government Support and Investment - The company reported a significant increase in government subsidies, totaling CNY 660,725.34, up 51.27% from CNY 436,777.60 in the previous year[7] - The company experienced a 92.94% increase in investment losses, reporting a loss of CNY -1,084,423.13 compared to CNY -562,047.23 in the previous year[7] Other Financial Metrics - The company reported a financial expense of CNY 6,752,926.59, which increased from CNY 4,190,943.25 in the previous year[16] - The company incurred a loss of CNY 36,219.89 from asset disposal, compared to a loss of CNY 14,514.63 in the previous year[17] - The company received CNY 30,015,998.80 in tax refunds, an increase from CNY 17,826,514.07 in the previous year[20] Operational Performance - Total operating revenue for Q1 2022 was CNY 511,351,040.77, a decrease of 12.6% compared to CNY 585,539,472.88 in the same period last year[16] - Total operating costs for Q1 2022 were CNY 453,050,530.40, down 12.0% from CNY 514,947,064.30 year-on-year[16] Product Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[11]